Menu
Aleva Neurotherapeutics started as a spin-off of the Swiss Federal Institute of Technology in Lausanne, Switzerland, with the objective of improving the existing Deep Brain Stimulation treatment for patients suffering from Neurological Disorders.
We believe this goal can be reached by improving the manufacturing methods, utilising more sophisticated technologies, and with a better focus on the daily needs of neurologists and neurosurgeons.
One of Aleva’s distinguishing elements is the use of MEMS (Micro-ElectroMechanical System) technology to neuromodulation.
The directSTIM™ 12 electrode lead is based on the technology developed at the Swiss Federal Institute of Technology (EPFL) Microsystems Laboratory of Prof. Philippe Renaud (www.lmis4.epfl.ch).
Our technology allows us to manufacture micro-smooth surfaces and electrode shapes specifically designed for the brain.
Our implantable leads prevent stimulation hot spots and induce fewer artefacts in post-operative images
We are the only European company that designs, manufactures, and commercialises a full DBS system for the treatment of Parkinson’s Disease and Essential Tremor.
Today, Aleva is a commercial-stage company that following directSTIM™’s CE marking, has started its commercial journey by partnering with the leading neurological clinics in Europe, aiming to penetrate the most relevant worldwide markets in the near future.
Transforming Deep Brain Stimulation treatment of neurological and psychiatric diseases by using unique technology and clinical data insight to power the surgical and programming experience in order to achieve better lives for patients.
Our DNA is based on disruptive innovation, and we are committed to continuing to develop technologies well ahead of the curve.
We’re working to create a digital ecosystem that gathers and elaborates patient’s clinical data to generate insights. This new information will power the surgical and programming experience to achieve better lives for patients.
We’re working on new implantations to improve patient’s comfort and outcomes.
We are investing significant resources in adding new indications to our pipeline of therapies, expanding to meet clinical needs well beyond Parkinson’s Disease. We are looking at diseases where drug therapies have failed or induce significant side effects, and a surgical approach can become a standard of care.